organism: Homo sapiens
description: B-CLL Sample24 - Human B-chronic lymphocytic leukemia - Sample24
attributes.tag: cell type
attributes.value: B-cell
attributes.tag: geographic location (country and/or sea)
attributes.value: Italy
attributes.tag: sample name
attributes.value: 24
attributes.tag: scientific name
attributes.value: Homo Sapiens
attributes.tag: sex
attributes.value: male
attributes.tag: submission description
attributes.value: In B-chronic lymphocytic leukemia (B-CLL) the interaction between leukemic cells and the environmental niches confers drug resistance and promotes tumor cells survival. The Bruton's tyrosine kinase inhibitor ibrutinib is one of the first-in-class molecules available for the treatment of B-CLL patients able to disrupt the microenvironment protection. However, the emerging mechanisms of resistance affecting patients' survival call for new therapeutic strategies. The purpose of the current study was to investigate the ability of ibrutinib plus the MDM2-inhibitor nutlin-3 to counteract the tumor microenvironment protective effect
attributes.tag: submission identifier
attributes.value: GSB-1351
attributes.tag: submission title
attributes.value: Dual BTK and MDM2 inhibition effects in microenvironment protected chronic lymphocytic leukemia cells
attributes.tag: tissue type
attributes.value: Blood